ANVS · Annovis Bio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-20 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
18,849 |
| 2026-05-20 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
54,933 |
| 2026-05-20 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,562 |
| 2026-04-02 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
713,800 |
| 2025-12-08 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
30,000 |
| 2025-12-08 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
15,000 |
| 2025-11-24 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
9,200 |
| 2025-11-24 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
1,489 |
| 2025-11-24 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
415 |
| 2025-11-24 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
28,096 |
| 2025-11-21 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
10,000 |
| 2025-11-21 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
10,000 |
| 2025-11-14 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
15,000 |
| 2025-10-28 | Hoffman Michael B |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
975,610 |
| 2025-10-28 | Maccecchini Maria-Luisa |
Director |
Buy↑
|
Common Stock
|
97,561 |
| 2025-09-10 | Bruck Claudine |
Director |
Convert↓
|
Option
|
7,142 |
| 2025-09-10 | Bruck Claudine |
Director |
Convert↑
|
Common Stock
|
7,142 |
| 2025-08-29 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,000 |
| 2025-08-29 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,000 |
| 2025-08-29 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,000 |
| 2025-08-19 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,283 |
| 2025-08-19 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
1,100 |
| 2025-08-19 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
6,717 |
| 2025-08-19 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,545 |
| 2025-06-16 | Walsh Andrew |
Vice President, Finance |
Award↑
|
Common Stock
|
500 |
| 2025-06-13 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
1 |
| 2025-06-13 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
25,000 |
| 2025-06-10 | McCarthy Reid |
Director |
Award↑
|
Common Stock
|
2,000 |
| 2025-06-04 | Maccecchini Maria-Luisa |
Director |
Award↑
|
Common Stock
|
46,000 |
| 2025-05-29 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,000 |
| 2024-07-01 | White Mark K. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The stock option was granted in consideration for consulting services that reporting person will perform for the Company. The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement. |
Stock Option (right to buy)
|
20,000 |
| 2024-03-31 | Maccecchini Maria-Luisa |
Director |
Gift↓
Filing footnotes — Common Stock (Direct)
Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. |
Common Stock
|
10,000 |
| 2024-03-31 | Maccecchini Maria-Luisa |
Director |
Gift↓
Filing footnotes — Common Stock (Direct)
Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. |
Common Stock
|
10,000 |
| 2024-03-28 | Maccecchini Maria-Luisa |
Director |
Gift↓
Filing footnotes — Common Stock (Direct)
Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. |
Common Stock
|
10,000 |
| 2023-11-27 | White Mark K. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The stock option was granted in consideration for consulting services that reporting person will perform for the Company. The stock option shall vest immediately upon grant date. |
Stock Option (right to buy)
|
2,146 |
| 2023-11-20 | McCarthy Reid |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
This amendment is being filed solely to reverse the previously reported purchase on the original form 4 filed on November 21, 2023 (the "Original Form 4"). Such purchase was rescinded by the registrant and the reporting person on November 22, 2023. |
Common Stock
|
0 |
| 2023-11-20 | Hagopian Henry III |
Chief Financial Officer |
Award↑
|
Common Stock
|
820 |
| 2023-11-20 | Maccecchini Maria-Luisa |
Director |
Award↑
|
Common Stock
|
40,970 |
| 2023-11-20 | White Mark K. |
Director |
Award↑
|
Common Stock
|
1,990 |
| 2023-11-20 | Bruck Claudine |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
This amendment is being filed solely to reverse the previously reported purchase on the original form 4 filed on November 21, 2023 (the "Original Form 4"). Such purchase was rescinded by the registrant and the reporting person on November 22, 2023. |
Common Stock
|
0 |
| 2023-11-20 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Indirect)
The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. |
Common Stock
(I)
|
163,880 |
| 2023-11-17 | Maccecchini Maria-Luisa |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025. |
Stock Option (right to buy)
|
252,000 |
| 2023-11-17 | Maccecchini Maria-Luisa |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved. The stock option shall vest immediately. |
Stock Option (right to buy)
|
108,800 |
| 2023-11-17 | McCarthy Reid |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. The stock option shall vest immediately upon grant date. |
Stock Option (right to buy)
|
29,600 |
| 2023-11-17 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. The stock option shall vest immediately upon grant date. |
Stock Option (right to buy)
|
29,600 |
| 2023-11-17 | White Mark K. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. The stock option shall vest immediately upon grant date. |
Stock Option (right to buy)
|
26,200 |
| 2023-11-17 | Bruck Claudine |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. The stock option shall vest immediately upon grant date. |
Stock Option (right to buy)
|
26,200 |
| 2023-04-24 | Maccecchini Maria-Luisa |
Director |
Gift↓
|
Common Stock
|
3,000 |
| 2023-04-07 | Hoffman Michael B |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Indirect)
The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. |
Common Stock
(I)
|
59,477 |
| 2023-04-07 | Maccecchini Maria-Luisa |
Director |
Award↑
|
Common Stock
|
20,000 |